Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The time window for intravenous recombinant tissue plasminogen activator treatment in ischemic stroke patients has been extended to 4.5h. Little is known about intravenous recombinant tissue plasminogen activator use in the 3-4.5 hour time window among Chinese stroke patients. This exploratory study was to describe the feasibility and outcome of treatment with intravenous recombinant tissue plasminogen activator in the expanded time window, and to offer suggestions for future clinical work in China.
Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was assessed by absolute changes in the National Institute of Health Stroke Scale score at 24 hours and by the improvement of modified Rankin Scale score at discharge or 6-month follow-up. The safety of intravenous recombinant tissue plasminogen activator was assessed by the rate of mortality, intracerebral hemorrhage and other common complications. Multivariate logistic regression models were used to evaluate factors associated with favorable clinical outcome.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| recombinant tissue plasminogen activator | Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h. |
| |
| rt-PA | One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| IV rt-PA | Drug | IV rt-PA treatment |
|
| Measure | Description | Time Frame |
|---|---|---|
| National Institute of Health Stroke Scale score and modified Rankin Scale | Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was assessed by absolute changes in the National Institute of Health Stroke Scale score at 24 hours and by the improvement of modified Rankin Scale score at discharge or 6-month follow-up | Outcome measure will be assessed at 24 weeks |
Not provided
Not provided
Inclusion Criteria:stroke patients in the 3-4.5 hour time window -
Exclusion Criteria:stroke patients in more than 4.5 hour time window
-
Not provided
Not provided
stroke patients in the 3-4.5 hour time window
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wuhan G H, High | Wuhan General Hospital of Guangzhou Command | Study Chair |
Not provided
Not provided
| Label | URL |
|---|---|
| Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |